Marketed and experimental medicines for the
treatment of Diabetes

Company	Product name /code	Product type	Phase of development	Comments
Abbott	ABT-894	Nicotinic receptor antagonist	Phase 1	For neuropathic pain
Amgen	AMG 131	PPAR agonist, gamma	Phase 2
Amylin	Pramlintide	Amylin analogue	Submitted	Registered in the US
Astellas	FK-614	PPAR agonist, gamma	Phase 2
AstraZeneca	Tesaglitazar	PPAR agonist, dual	Phase 3
	AZD 6610	PPAR agonist, dual	Phase 1
Bayer	Acarbose	Alpha-glucosidase inhibitor	Registered
Bristol-Myers Squibb	Muraglitazar	PPAR agonist, dual	Phase 3	Collaboration with MSD
	Saxagliptin	DPP-IV inhibitor	Phase 2
Diamyd Medical	GAD protein	Glutamic acid decarboxylase protein	Phase 2	Diabetes type 1
Eli Lilly	Exenatide	GLP-1 analogue	Submitted	Registered in the US
	Insulin NPH	Human	Registered
	Insulin, biphasic mix	Human	Registered
	Insulin, rapid-acting	Human	Registered
	Inhaled insulin	Insulin, inhaled	Phase 3
	Ruboxistaurin	Protein Kinase C beta inhibitor	Phase 3	For diabetic retinopathy
	Ruboxistaurin	Protein Kinase C beta inhibitor	Phase 3	For neuropathic pain
	Exenatide LAR	GLP-1 analogue	Phase 2
	Naveglitazar	PPAR agonist, gamma	Phase 2
	Ruboxistaurin	Protein Kinase C beta inhibitor	Phase 2	For diabetic nephropathy
	TS-021	DPP-IV inhibitor	Phase 1
Generex Biotech	Buccal insulin	Insulin, oral spray (buccal)	Phase 2
GSK	Rosiglitazone + Sulphonylurea	PPAR-gamma + sulphonylurea fixed comb.	Submitted
	Rosiglitazone	Thiazolidinedione	Registered
	Rosiglitazone + Metformin	PPAR-gamma + metformin fixed comb.	Registered
	677954	PPAR agonist, pan-	Phase 2
	Denagliptan	DPP-IV inhibitor	Phase 2
	869682	Na-dep. glucose transport inhibitor	Phase 2
	189075	Na-dep. glucose transport inhibitor	Phase 1
GW Pharma	THC:CBD	Cannabis-derived spray	Phase 2	For neuropathic pain
Ipsen	BIM 51077	GLP-1 analogue	Phase 1
Kissei	KAD-1229	Meglitinide	Phase 3
Merck	Metformin	Biguanide	Registered
	Metformin Sustained Release	Biguanide	Registered
Metabolex Inc	Metaglidasen	PPAR modulator, selective	Phase 2
	MBX-2044	PPAR modulator, selective	Phase 1
Mitsubishi	Netoglitazone	PPAR agonist, dual	Phase 2	Collaboration with Perlegen
MSD	Sitagliptin	DPP-IV inhibitor	Phase 3
Novartis	Nateglinide	Meglitinide analogue	Registered
	Nateglinide +Valsartan	Meglitinide + Angiotensin Receptor Blocker	Phase 4	NAVIGATOR trial
	Octreotide	Somatostatin analogue	Phase 3	For diabetic retinopathy
	Vildagliptin	DPP-IV inhibitor	Phase 3
Novo Nordisk	Insulin Detemir	Insulin, long-acting	Registered
	Repaglinide	Meglitinide analogue	Registered
	Inhaled insulin	Insulin, inhaled	Phase 3
	Liraglutide	GLP-1 analogue	Phase 3
	Insulin NPH	Human & porcine insulin	Registered
	Insulin, biphasic mix	Human	Registered
	Insulin, long-acting	Human	Registered
	Insulin, rapid-acting	Human & Pork	Registered
Pfizer	Inhaled insulin	Insulin, dry powder	Submitted	Collaboration with sanofi-aventis
	Glipizide	Sulphonylurea	Registered
	Pegaptanib	Pegylated anti-VEGF aptamer	Phase 2	For diabetic retinopathy
Prosidion	PSN9301	DPP-IV inhibitor	Phase 2
	PSN357	DPP-IV inhibitor	Phase 1
Roche	R1438	DPP-IV inhibitor	Phase 2
	R483	PPAR agonist, gamma	Phase 2
	R1439	PPAR agonist, dual	Phase 1
	R1440	Glucokinase activator	Phase 1
	R1499	DPP-IV inhibitor	Phase 1
Sankyo	CS-917	Fructose 1,6-bisphosphatase inhibitor	Phase 2
	CS-872	GLP-1 nasal spray	Phase 2
	Fidarestat	Aldose Reductase Inhibitor	Phase 2
	Rivoglitazone	PPAR agonist, gamma	Phase 2
Sanofi-aventis	Insulin Glulisine	Insulin, fast-acting	Submitted
	Glibenclamide	Sulphonylurea	Registered
	Glimepiride	Sulphonylurea	Registered
	Gliquidone	Sulphonylurea	Registered
	Insulin Glargine	Insulin long-acting	Registered
	Insulin NPH	Human	Registered
	Insulin, biphasic mix	Human	Registered
	Insulin, rapid-acting	Human	Registered
	Irbesartan	Angiotensin Receptor Blocker	Registered	For diabetic nephropathy
	AVE0010	GLP-1 analogue	Phase 2
	AVE0847	PPAR agonist, dual	Phase 2
	AVE8134	PPAR agonist, alpha	Phase 2
	AVE2268	Sodium-dep. glucose transport inhibitor	Phase 1
	AVE5688	Glycogen phosphorylase inhibitor	Phase 1
Servier	Gliclazide	Sulphonylurea	Registered
Speedel	SPP301	Oral endothelin-A antagonist	Phase 2	For diabetic nephropathy
Takeda	Pioglitazone	Thiazolidinedione	Registered
	Candesartan cilexetil	Angiotensin Receptor Blocker	Phase 3	Retinopathy (DIRECT trials)
	SYR-322	DPP-IV inhibitor	Phase 2
	TAK-128	Myelin formation accelerator	Phase 2	For diabetic neuropathy
	TAK-428	Neurotrophic factor production accelerator	Phase 2	For diabetic neuropathy
	TAK-583		Phase 2	For diabetic neuropathy
	TAK-654	PPAR agonist, dual	Phase 2
Wyeth	Perzinfotel	NMDA antagonist	Phase 2	For diabetic neuropathy
	PLX204	PPAR agonist, alpha/gamma/delta	Phase 1
Notes: All products authorised/in development for diabetes type 2, and insulins for types 1 and 2, unless otherwise stated. Key: comb. – combination; dep. – dependent; DPP dipeptidyl peptidase; GLP-1 – glucagon-like peptide-1; PPAR – peroxisome proliferator activated receptor; rh – recombinant, human; VEGF – vascular endothelial growth factor.

< Previous Page | Contents | Next Page >